Ryvu Therapeutics is focused on developing innovative small molecule therapies that target emerging areas in oncology, particularly through its pipeline of kinase inhibitors, synthetic lethality programs, and immuno-oncology initiatives. One of the key programs is RVU120, a selective inhibitor of CDK8 and CDK19, which is currently in Phase II clinical trials for treating relapsed/refractory acute myeloid leukemia (AML) and advanced solid tumors. This compound has shown promising results in preclinical models, demonstrating significant anti-tumor activity and a manageable safety profile. Additionally, Ryvu is advancing RVU305, a PRMT5 inhibitor, and exploring synthetic lethality strategies through its proprietary ONCO Prime platform, which aims to identify novel therapeutic targets by leveraging patient-derived models.

In collaboration with nCage Therapeutics, Ryvu is also developing a next-generation antibody-drug conjugate (ADC) platform that utilizes a novel drug delivery system to enhance the efficacy and safety of ADCs. This partnership aims to improve the antibody-to-drug ratio, potentially leading to less toxic treatments and broader patient applicability. Ryvu's research encompasses a range of therapeutic mechanisms, including targeting oncogenic drivers like KRAS and developing selective inhibitors for specific cancer types, thereby positioning the company at the forefront of oncology innovation.

Poland

Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies addressing high value emerging targets in cancer and other serious diseases.

Ryvu Therapeutics

Company Details